This organism has received latest press attention because staff wounded by IEDs or combat in the Middle East display an extraordinarily high incidence of MDR Acinetobacter attacks. Furthermore, MDR Acinetobacter causes periodic outbreaks in hospitals and is much more difficult to take care of or eradicate than MRSA. Some doctors think that Acinetobacter and very similar organisms present a greater and more imminent threat than MRSA. Strains that remain susceptible to just a few antibiotics are increasingly common. Accelr8’s scientists have shown that the BACcel program can easily and accurately identify multiple strains of Acinetobacter extracted from lung fluids. The timing cannot become better, since we’ re accelerating the pace of our study publication.An interview with Dr Matt SilverSome antibiotics might make MRSA even more harmfulInner ear damage brain warnings from nerve cells ‘Europe represents an enormous potential market for us, the world's following the U largest.S., so we are especially very happy to now be past the halfway point in all three of our clinical trials on both continents,’ commented Gary Rabin, chairman and CEO of ACT. ‘SMD affects as many as 100,000 individuals in the U.S. And Europe. Furthermore, as announced previously, the European Medicines Agency's Committee for Orphan Medicinal Items officially granted our hESC-derived RPE cells orphan medicinal product designation for the treatment of SMD.